ENVVENO MEDICAL CORP (NVNO)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$7.00-2.50%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
QuarterlyIQ Insights · NVNO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 28 industry peers · Company calendar date is not available
NVNO — litigation filed
Dated 2026-04-29
Regulation FD Disclosure. On April 29, 2026, the Company issued a press release announcing the Company had received a favorable decision from the U.S. Food & Drug Administration in connection with the Company’s Investigational Device Exemption application for the Transcatheter Venous Valve Endoprosthesis (TAVVE ® ) pivotal study. The press release is being furnished as Exhibit 99.1 to this Current Report. Statements that are not historical fact may be considered forward-looking statements wit…
Why it matters: The company reported cash to fund operations into Q3 2027. Trial costs and ongoing losses could shorten that runway.
Worry ifA company update says cash may last only through Q1 2027 or less. It may also report a need for financing before then.
Less concerning ifA later cash update says funds can support operations into Q3 2027 or beyond. No new financing is announced.
Why it matters: The latest stated cash burn was $3.24 million. A higher burn could use up cash faster as the trial starts.
Worry ifA reported quarter shows cash flow burn worse than negative $3.24 million.
Less concerning ifA reported quarter shows cash flow burn of negative $3.24 million or less, with no shorter cash runway stated.
Why it matters: The FDA will review safety data before the larger study starts. A clean review would let the trial move ahead.
Supportive ifThe company reports 30-day safety results for its first 10 patients to the FDA. The FDA lets stage two enrollment begin.
Worry ifThe FDA pauses or delays stage two enrollment, or the first 10 patients show a safety issue that needs more review.
Why it matters: Starting on time would show that sites are ready and the pivotal trial is moving forward. A delay would push back key study results.
Supportive ifThe company confirms the first patient has been enrolled in TAVVE by December 31, 2026.
Worry ifThe company reports that no first patient enrolled by December 31, 2026. It also reports delayed site activation.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$255 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $881 loss on $10,000 · 8.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,261 loss on $10,000 · 72.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.